Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of ... Bristol-Myers Squibb Company and AbbVie today announced updated efficacy and safety data from a small, randomized Phase 2, open-label study in patients with previously-treated multiple myeloma that evaluated two doses of the investigational monoclonal antibody elotuzumab in combination with lenalidomide and low-dose dexamethasone.
June 15, 2013 - Business Wire via Yahoo! Finance
Immunomedics to Present at Wells Fargo Securities 2013 Healthcare Conference MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other ...
June 14, 2013 - GlobeNewswire via Yahoo! Finance